ArticleDiscover oncology2025
Multiple primary cancers with prostate malignant tumor as the initial diagnosis: a case report.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
With the advancement of medical technology and improvements in living standards, the survival time of many cancer patients has been prolonged. However, a significant proportion of these patients develop multiple primary cancers (MPC), which indicates a poorer prognosis. Currently, there are no specific guidelines for managing MPC. This article reports a rare case of an elderly male patient who, during a six-year follow-up period, was diagnosed with four primary tumors in different organs including prostate cancer (first manifestation), renal cancer, bladder cancer, and lung cancer. Genetic testing of tumor tissues revealed an EGFR mutation in the lung cancer tissue and BAP1 gene deletion in the renal cancer tissue. Over the six-year follow-up, the patient underwent radical prostatectomy, partial nephrectomy, transurethral resection of bladder tumor, and radical left lung resection, with good postoperative recovery. This case represents MPC involving three urogenital system tumors and highlights the rare coexistence of EGFR mutation and BAP1 gene deletion across different organ-specific cancers. It underscores the necessity of genetic testing for MPC patients and demonstrates that aggressive management of primary tumors can improve the patient's quality of life. This case provides valuable insights for clinical research and treatment strategies for MPC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.